Hu W - Search Results

1

Anticancer therapy targeting the apoptotic pathway.

Hu W, Kavanagh JJ. Hu W, et al. Lancet Oncol. 2003 Dec;4(12):721-9. doi: 10.1016/s1470-2045(03)01277-4. Lancet Oncol. 2003. PMID: 14662428 Review.

2

Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines.

Hu W, Verschraegen CF, Wu WG, Nash M, Freedman RS, Kudelka A, Kavanagh JJ. Hu W, et al. Int J Gynecol Cancer. 2002 Mar-Apr;12(2):202-7. doi: 10.1046/j.1525-1438.2002.01084.x. Int J Gynecol Cancer. 2002. PMID: 11975681

3

Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor.

Hu W, Wu W, Yeung SC, Freedman RS, Kavanagh JJ, Verschraegen CF. Hu W, et al. Anticancer Res. 2002 Mar-Apr;22(2A):665-72. Anticancer Res. 2002. PMID: 12014635

4

Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.

Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC. Verschraegen CF, et al. Among authors: hu w. Clin Cancer Res. 2003 Feb;9(2):845-52. Clin Cancer Res. 2003. PMID: 12576458

5

Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.

Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman L, McCubrey JA, Andreeff M. Carter BZ, et al. Among authors: hu w. Leukemia. 2003 Nov;17(11):2081-9. doi: 10.1038/sj.leu.2403113. Leukemia. 2003. PMID: 12970762

6

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.

Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Völker P, Kavanagh J, Steger M, Schulz KD, Emons G. Verschraegen CF, et al. Among authors: hu w. Gynecol Oncol. 2003 Sep;90(3):552-9. doi: 10.1016/s0090-8258(03)00408-6. Gynecol Oncol. 2003. PMID: 13678723 Clinical Trial.

7

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.

Verschraegen CF, Kudelka AP, Hu W, Vincent M, Kavanagh JJ, Loyer E, Bastien L, Duggal A, De Jager R. Verschraegen CF, et al. Among authors: hu w. Cancer Chemother Pharmacol. 2004 Jan;53(1):1-7. doi: 10.1007/s00280-003-0696-7. Epub 2003 Oct 28. Cancer Chemother Pharmacol. 2004. PMID: 14586557 Clinical Trial.

8

Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor.

Hu W, Wu W, Verschraegen CF, Chen L, Mao L, Yeung SC, Kudelka AP, Freedman RS, Kavanagh JJ. Hu W, et al. Proteomics. 2003 Oct;3(10):1904-11. doi: 10.1002/pmic.200300547. Proteomics. 2003. PMID: 14625852

9

Proteomics in cancer screening and management in gynecologic cancer.

Hu W, Wu W, Kobayashi R, Kavanagh JJ. Hu W, et al. Curr Oncol Rep. 2004 Nov;6(6):456-62. doi: 10.1007/s11912-004-0076-4. Curr Oncol Rep. 2004. PMID: 15485615 Review.

10

Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer.

Hu W, Kavanagh JJ, Deaver M, Johnston DA, Freedman RS, Verschraegen CF, Sen S. Hu W, et al. Oncol Res. 2005;15(1):49-57. doi: 10.3727/096504005775082101. Oncol Res. 2005. PMID: 15839305

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,508 results

Search Page

Filters